Unnamed: 0,title,date,stock,sentiment
11093.0,Abiomed Reports FDA Approval Of Co.'s Impella ECP Heart Pump,2020-06-05 07:01:00-04:00,ABMD,positive
11094.0,FDA Issues Emergency Use Authorization For Impella RP As Therapy For Covid-19 Coronavirus Patients With Right Heart Failure,2020-06-01 07:05:00-04:00,ABMD,negative
11095.0,10 Biggest Price Target Changes For Thursday,2020-05-28 08:22:00-04:00,ABMD,neutral
11096.0,"SVB Leerink Reiterates Market Perform on Abiomed, Raises Price Target to $225",2020-05-28 06:52:00-04:00,ABMD,neutral
11097.0,"Morgan Stanley Maintains Underweight on Abiomed, Raises Price Target to $152",2020-05-01 07:48:00-04:00,ABMD,neutral
11098.0,"SVB Leerink Maintains Market Perform on Abiomed, Raises Price Target to $195",2020-05-01 06:52:00-04:00,ABMD,neutral
11099.0,72 Biggest Movers From Yesterday,2020-05-01 05:29:00-04:00,ABMD,neutral
11100.0,61 Stocks Moving In Thursday's Mid-Day Session,2020-04-30 12:43:00-04:00,ABMD,neutral
11101.0,Abiomed shares are trading higher after the company reported better-than-expected Q4 EPS results.,2020-04-30 11:15:00-04:00,ABMD,positive
11102.0,"The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1",2020-04-30 07:19:00-04:00,ABMD,positive
11103.0,"Abiomed Q4 Adj. EPS $1.000 Beats $0.940 Estimate, Sales $206.658M Miss $207.170M Estimate",2020-04-30 07:12:00-04:00,ABMD,negative
11104.0,"Benzinga's Top Upgrades, Downgrades For April 27, 2020",2020-04-27 09:32:00-04:00,ABMD,positive
11105.0,10 Biggest Price Target Changes For Monday,2020-04-27 08:28:00-04:00,ABMD,neutral
11106.0,"SVB Leerink Downgrades Abiomed to Market Perform, Lowers Price Target to $175",2020-04-27 07:30:00-04:00,ABMD,negative
11107.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,ABMD,negative
11108.0,30 Stocks Moving in Thursday's Pre-Market Session,2020-04-09 07:10:00-04:00,ABMD,neutral
11109.0,"Morgan Stanley Maintains Underweight on Abiomed, Lowers Price Target to $149",2020-03-27 08:32:00-04:00,ABMD,negative
11110.0,10 Stocks To Buy With Low Debt And High Liquidity,2020-03-27 08:15:00-04:00,ABMD,negative
11111.0,"The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test",2020-03-24 08:20:00-04:00,ABMD,negative
11112.0,"Stephens & Co. Maintains Overweight on Abiomed, Lowers Price Target to $155",2020-03-23 11:14:00-04:00,ABMD,negative
11113.0,Stocks That Hit 52-Week Lows On Monday,2020-03-23 10:34:00-04:00,ABMD,negative
11114.0,Stocks That Hit 52-Week Lows On Monday,2020-03-16 11:51:00-04:00,ABMD,negative
11115.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,ABMD,negative
11116.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,ABMD,negative
11117.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,ABMD,negative
11118.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,ABMD,negative
11119.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,ABMD,neutral
11120.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,ABMD,negative
11121.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,ABMD,positive
11122.0,"Benzinga's Top Upgrades, Downgrades For February 12, 2020",2020-02-12 09:40:00-05:00,ABMD,positive
11123.0,"Morgan Stanley Downgrades Abiomed to Underweight, Lowers Price Target to $165",2020-02-12 04:51:00-05:00,ABMD,negative
11124.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,ABMD,negative
11125.0,"Abiomed Q3 Adj. EPS $1.12 Beats $1.09 Estimate, Sales $221.6M Miss $226.85M Estimate",2020-02-06 07:15:00-05:00,ABMD,negative
11126.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,ABMD,neutral
11127.0,27 Medical Devices Stocks Moving In Tuesday's Session,2020-01-21 14:36:00-05:00,ABMD,neutral
11128.0,85 Biggest Movers From Yesterday,2020-01-14 04:52:00-05:00,ABMD,neutral
11129.0,41 Stocks Moving In Monday's Mid-Day Session,2020-01-13 12:21:00-05:00,ABMD,neutral
11130.0,Abiomed shares are trading lower after the company issued Q3 and FY20 sales guidance below analyst estimates.,2020-01-13 07:57:00-05:00,ABMD,neutral
11131.0,"Abiomed Sees Prelim. Q3 Sales $221.6M vz $226.68M Est., Sees FY20 Sales $856M-$877M vs $885.77M Est.",2020-01-13 07:24:00-05:00,ABMD,neutral
11132.0,10 Best Performing S&P 500 Stocks Of The Decade,2019-12-31 15:01:00-05:00,ABMD,positive
11133.0,10 Worst Performing S&P 500 Stocks Of 2019,2019-12-24 11:18:00-05:00,ABMD,negative
11134.0,10 Stocks That Could Be Tax-Loss Buying Opportunities,2019-12-19 12:21:00-05:00,ABMD,positive
11135.0,"Morgan Stanley Maintains Equal-Weight on Abiomed, Lowers Price Target to $198",2019-12-17 08:54:00-05:00,ABMD,negative
11136.0,"Cramer Weighs In On Biogen, Caterpillar And More",2019-12-03 11:22:00-05:00,ABMD,neutral
11137.0,UPDATE: Abiomed Highlights 3 Flaws Of Impella Analysis Provided By Amin At American Heart Association Conference,2019-11-19 13:17:00-05:00,ABMD,neutral
11138.0,Abiomed Issues Press Release Highlighting Issuance Of Publication Review Of Observational Analysis Of Impella Previously Presented By Amin At American Heart Association Conference On Nov. 17,2019-11-19 13:14:00-05:00,ABMD,neutral
11139.0,72 Biggest Movers From Yesterday,2019-11-19 04:39:00-05:00,ABMD,neutral
11140.0,44 Stocks Moving In Monday's Mid-Day Session,2019-11-18 12:32:00-05:00,ABMD,neutral
11141.0,"Abiomed shares are trading lower after studies suggest the Impella heart device is associated with an increased risk of death, bleeding, and stroke among patients undergoing angioplasty to re-open clogged arteries.",2019-11-18 11:35:00-05:00,ABMD,negative
11142.0,"Abiomed Announces First U.S. Patients Have Been Treated with Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump",2019-10-31 09:28:00-04:00,ABMD,neutral
11143.0,Abiomed shares are trading higher after the company reported its Q2 earnings results and issued FY20 sales guidance of $885M - $925M vs $895M analyst estimate.,2019-10-31 08:25:00-04:00,ABMD,positive
11144.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,ABMD,positive
11145.0,12 Stocks With The Highest Returns On Assets,2019-10-29 13:00:00-04:00,ABMD,positive
11146.0,"Benzinga's Top Upgrades, Downgrades For October 29, 2019",2019-10-29 10:49:00-04:00,ABMD,positive
11147.0,Raymond James Downgrades Abiomed to Market Perform,2019-10-29 07:56:00-04:00,ABMD,neutral
11148.0,"Abiomed Highlights FDA Post-Approval Study Shows Timely Identification Of Right Heart Failure, Early Use Of Impella RP Leads To Higher Survival",2019-10-25 08:05:00-04:00,ABMD,negative
11149.0,16 Stocks With The Highest Long-Term Sales Growth Rate,2019-10-23 15:26:00-04:00,ABMD,positive
11150.0,Abiomed shares are trading higher on news of a longer-than-expected completion date for competitor Abbott's Shield II study of its HeartMate PHP catheter.,2019-10-23 12:53:00-04:00,ABMD,positive
11151.0,Clinicaltrials.gov Site Shows Completion Date For Abbott's Shield II Percutaneous Heart Pump Was Pushed Back One Year,2019-10-23 11:25:00-04:00,ABMD,neutral
11152.0,13 Stocks With The Highest EPS Growth Over The Past 5 Years,2019-10-21 14:00:00-04:00,ABMD,positive
11153.0,"Cramer Advises His Viewers On Beyond Meat, Texas Instruments And More",2019-10-21 11:28:00-04:00,ABMD,neutral
11154.0,Stocks That Hit 52-Week Lows On Thursday,2019-10-10 11:08:00-04:00,ABMD,negative
11155.0,"The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO",2019-10-10 07:31:00-04:00,ABMD,neutral
11156.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-09 12:55:00-04:00,ABMD,negative
11157.0,"The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug",2019-10-09 07:58:00-04:00,ABMD,negative
11158.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-08 12:02:00-04:00,ABMD,negative
11159.0,"Abiomed Announces the 1,000th Patient was Treated with Impella in Japan",2019-10-07 08:04:00-04:00,ABMD,neutral
11160.0,Stocks That Hit 52-Week Lows On Thursday,2019-10-03 13:03:00-04:00,ABMD,negative
11161.0,"The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo",2019-10-03 07:34:00-04:00,ABMD,negative
11162.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-02 10:55:00-04:00,ABMD,negative
